Equillium (0A4D) AI Stock Analysis

2 Followers

Equillium

(LSE:0A4D)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low LeverageVery low debt relative to equity gives Equillium a conservative capital structure and limits interest or refinancing pressure. This financial flexibility can help preserve resources for clinical development and reduce balance-sheet risk while the company remains pre-profit.

Negative Factors

No Current RevenueZero current revenue alongside a sizable net loss shows that Equillium has not yet established an operating revenue base. Until a product or partnership generates recurring income, financial performance will remain dependent on clinical progress and access to external funding.

Equillium (0A4D) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: $90.04M
Dividend Yield: ―
Average Volume (3M): 2,914
Price to Earnings (P/E): -5.5
Beta (1Y): -0.05
Revenue Growth: -100.00%
EPS Growth: 64.23%
Country: UK
Employees: 14
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Equillium Business Overview & Revenue Model

Company Description

Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficien...

Equillium Risk Analysis

Equillium disclosed 86 risk factors in its most recent earnings report. Equillium reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks

1.Risk factors summaryQ2, 2026

2.Risks Related to Our Financial Position and Need for Additional CapitalQ2, 2026

3.Risks Related to our Business and to the Development and Regulatory Approval of our Product CandidatesQ2, 2026

Equillium Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0A4D against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NRXP	46Neutral	$103.01M	-3.28	168.68%	―	―	67.07%
HYFT	45Neutral	$49.00M	-4.02	-144.31%	―	-26.89%	56.50%
STRO	42Neutral	$168.63M	-0.59	185.30%	―	-56.25%	30.97%
PRLD	38Underperform	$300.06M	-4.78	-75.35%	―	220.34%	55.73%

* Healthcare Sector Average

Performance Comparison

GB:0A4D and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0A4D	Equillium	1.44	0.43	42.49%
NRXP	Nrx Pharmaceuticals, Inc.	2.44	-0.05	-2.01%
STRO	Sutro Biopharma	10.26	1.21	13.40%
HYFT	Mindwalk Holdings Corp.	1.03	-0.65	-38.69%
PRLD	Prelude Therapeutics, Inc.	3.78	2.26	148.68%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Equillium AI Stock Analysis